Develops novel cell therapies, primarily T-cell immunotherapies, for cancer patients. Focuses on genetically modifying autologous T-cells to target and destroy tumors. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
No real growth (-1% a year). Red columns mark years that ended in a loss.
If every debt were paid off today, $11.9M would still be left in the vault — a solid cushion for hard times.
The market pays 0.2× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Analysts' average target sits 12,394% above today's price.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $26.0M in the vault; even if every debt were paid off, $11.9M would remain.
The stock sits at $0.02. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Over the last 4 years, sales fell about 1% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.